WEDNESDAY,Mar, 2018(HealthDay News) — A newer drug may beat the standard treatment when it comes to battling the blood cancer follicular lymphoma, a clinical trial suggests.Follicular lymphoma is one type of non-Hodgkin lymphoma, a group of cancers that arise in white blood cells.The new study found that a drug called obinutuzumab (Gazyva) typically kept the cancer under control longer, versus the standard drug rituximab (Rituxan).

After three years, about 80 percent of obinutuzumab patients were showing no signs of cancer progression or relapse. That compared with roughly 73 percent of rituximab patients, according to the report.Cancer experts said the results, published in the Oct. 5 issue of the New England Journal of Medicine, are a positive step forward.But they do not necessarily mean obinutuzumab is the better choice for all patients, according to Dr. James Armitage, an oncologist at the University of Nebraska Medical Center, in Omaha.

Prev1 of 4
Continue Reading on Next Page


Leave A Reply